secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beta Bionics, Inc. (BBNX)
CIK:        0001674632
Form:       8-K
Filed at:   2026-09-15T20:58:41+00:00
Accession:  0001193125-26-392088
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears Beta Bionics Mint patch pump; 3D Intelligence 510(k) submitted
-------------------------------------------------------------------------

- Mint FDA clearance announced Sept 14, 2026; full U.S. launch expected Q1 2027, ahead of prior target; at least 1.5M disposable units capacity in 2027.
- 510(k) for 3D Intelligence insulin-dosing algorithm submitted; if cleared, powers iLet 3D by end 2026 and Mint 3D at launch.
- Mint launches exclusively via pharmacy channel; ~40% insured U.S. lives at launch, rising to ≥50% within first year.
- Real-world iLet data: >84% users meet ADA hypoglycemia goals; average HbA1c 8.9% to GMI 7.3% (n=14,952).
- Securities class action filed Sept 4, 2026 (Holtzman vs. Beta Bionics) alleging misstatements on iLet; company to defend vigorously.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674632/000119312526392088/0001193125-26-392088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674632/000119312526392088/d153052d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-392088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer